Sermorelin / Ipamorelin Blend

Cardiovascular Effects

Research in swine models demonstrates that sermorelin (as a GHRH agonist) reduces cardiomyocyte cell death, improves healing following cardiac injury, promotes collateral blood vessel growth, and reduces inflammation. Bagno et al. (2015) showed that GHRH agonists reduce myocardial infarct scar in subacute ischemic cardiomyopathy. Kanashiro-Takeuchi et al. (2015) demonstrated a therapeutic approach to heart failure based on targeting the GHRH receptor. A form of the ghrelin receptor has also been identified in cardiac tissue, and administration of ghrelin analogues has been shown to reduce arrhythmia risk and improve post-injury cardiac healing, as reviewed by Tokudome et al. (2019).

Central Nervous System and Sleep

Sermorelin has demonstrated benefits for the central nervous system in animal models. Tang et al. (2017) investigated interactions between GHRH and GABA-A receptors in the brain, suggesting roles in neuronal regulation. Research has also linked GHRH signaling to sleep quality improvement through modulation of slow-wave sleep architecture.

Bone Health

Ipamorelin has shown significant effects on bone metabolism. Andersen et al. (2001) demonstrated that ipamorelin counteracts glucocorticoid-induced decreases in bone formation in adult rats. Svensson et al. (2000) showed that ipamorelin and GHRP-6 increase bone mineral content in adult female rats, suggesting potential applications in osteoporosis research.

Metabolic and Gastrointestinal Effects

Adeghate & Ponery (2004) investigated the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats, indicating potential roles in glucose homeostasis. Beck et al. (2014) conducted a prospective, randomized, controlled study of ipamorelin for management of postoperative ileus in bowel resection patients, demonstrating its prokinetic properties.

Sermorelin (GHRH 1-29 analogue)

Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone and was the first GHRH analogue approved by the FDA (as Geref) for diagnosing and treating growth hormone deficiency in children. It acts on pituitary GHRH receptors to stimulate physiologic, pulsatile endogenous GH secretion, and was valued diagnostically because it produces fewer false-positive results than some other provocative tests. Commercial production was discontinued in 2008; current use is largely compounded and off-label.

• Daily subcutaneous sermorelin increased growth velocity in the majority of children with idiopathic GH deficiency.
• A single IV 1 mcg/kg dose serves as a rapid, relatively specific provocative test of GH deficiency.
• Less effective than recombinant GH and ineffective when the deficiency is of pituitary (rather than hypothalamic) origin.

Ipamorelin (selective GH secretagogue)

Ipamorelin is a pentapeptide ghrelin-receptor (GHS-R) agonist and one of the most selective GH secretagogues characterized, releasing GH with potency comparable to GHRP-6 but without meaningfully elevating ACTH, cortisol, or prolactin. It has never been approved for any indication; its most advanced human evaluation was a Phase 2 trial for postoperative ileus, which was safe but did not meet its efficacy endpoint. It remains a research-only compound.

• Highly selective for GH release with no significant cortisol/ACTH rise even at very high doses.
• Phase 2 postoperative ileus trial (NCT00672074) was well tolerated but not efficacious on the primary endpoint.
• Mechanistically complements GHRH analogues by acting on a distinct receptor (ghrelin/GHS-R), the basis for combining it with sermorelin.

The compounded blend (no direct evidence)

The sermorelin/ipamorelin blend is a compounded, non-FDA-approved product that pairs a GHRH analogue with a ghrelin-receptor agonist on the theory that stimulating GH release through two distinct receptor pathways yields greater or more physiologic GH output than either alone. Importantly, no clinical trials have evaluated the blend itself; all human evidence derives from the individual components, and safety/efficacy of the fixed combination is unestablished.

• No published clinical trials evaluate the combined blend.
• Rationale rests on dual-pathway GH stimulation (GHRH receptor + ghrelin receptor).
• Evidence base is limited to component data; combination claims are extrapolated, not demonstrated.